Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2010
03/24/2010CN101675924A Application of ascaridol in preparing medicine for preventing helicobacter pylori and treating disease caused by helicobacter pylori
03/24/2010CN101675923A New usage of zedoary cyclic diolefine
03/24/2010CN101675922A Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use
03/24/2010CN101675921A Method for preparing potassium aspartape raw medicine by physical method and preparation thereof
03/24/2010CN101675919A Sustained release tablet of intestinal tract flora metabolite 20(s)-ppt containing ginsenoside Rg1
03/24/2010CN101675918A Self-emulsifying micro-emulsion composition, preparation method and usage thereof
03/24/2010CN101675917A Propofol self-micro-emulsifying composition and preparation method thereof
03/24/2010CN101675916A Preparation method of levo-ofloxacin hyaluronic acid gel slow-released agent
03/24/2010CN101675912A cosmetic and dermatological formulations containing phenoxyalkyl esters
03/24/2010CN101675748A Novel tooth-protecting chewing gum
03/24/2010CN100595204C Bisamidate phosphonate prodrugs
03/24/2010CN100595200C Compound of dehydrogenated cavidine group and application in medication
03/24/2010CN100595199C Process for modifying drug crystal formation
03/24/2010CN100595198C Zedoary cyclo-diolefine and its derivatives preparation method and use
03/24/2010CN100595195C Preparation method and application of isoquinoline componds and salts thereof
03/24/2010CN100594935C Antibodies that immunospecifically bind to trail receptors
03/24/2010CN100594933C Antiobestic agents and health foods
03/24/2010CN100594926C Anti-microbial agent and anti-microbial composition
03/24/2010CN100594917C Externally applied medicine for curing psoriasis and producing method thereof
03/24/2010CN100594916C Plaster for reducing the blood pressure
03/24/2010CN100594912C Preparation of beauty gel for treating acne and preparing method
03/24/2010CN100594911C Medicine composition and use
03/24/2010CN100594910C Compound panoxatriol saponin with physiological activity and its preparation and use
03/24/2010CN100594909C Therapeutic agent for hemorrhoidal disease
03/24/2010CN100594908C Triamcinolone benetonide local film forming gel composition
03/24/2010CN100594907C Pharmaceutical formulation for contraception and hormone-replacement therapy
03/24/2010CN100594906C Process for preparing phytosterol dispersions for application in beverages
03/24/2010CN100594905C Benazepril pharmaceutical compsition and process for its preparation
03/24/2010CN100594904C Hydrochloride epinastine dispersing tablets and their production
03/24/2010CN100594903C HCV inhibiting bi-cyclic pyrimidines
03/24/2010CN100594902C Nano micelle preparation of Catharanthus roseus alkaloids antineoplastic drugs with coating of phospholipid derived from polyethylene glycol
03/24/2010CN100594901C Aqueous ophthalmic suspension of crystalline rebamipide
03/24/2010CN100594900C Application of alkaloid compounds in preparing antineoplastic medicaments
03/24/2010CN100594899C Sustained release system and method for ocular delivery of carbonic anhydrase inhibitors
03/24/2010CN100594898C Pharmaceutical composition of Silybin and preparation method thereof
03/24/2010CN100594897C Cannabinoid liquid formulations for mucosal amdinistration
03/24/2010CN100594896C Application of zedoary root cyclic diolefine in preparing medicament for treating tumour disease
03/24/2010CN100594895C Application of C22H34O3 for preparing chemicals for treating fish diseases, preparation and preparing method thereof
03/24/2010CN100594894C New formulation for retinoid-containing soft gelatin capsules
03/24/2010CN100594893C Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same
03/24/2010CN100594889C Penciclovir freeze dried and method of manufacturing the same
03/24/2010CN100594888C Pharmaceutical compositions suitable for the treatment of ophthalmic diseases
03/24/2010CN100594887C Anticancer slow release injection comprising tetrazole violet and potentiating agent thereof
03/24/2010CN100594886C Anticancer slow release agent loading both newborn blood vessel and tetrazole violet
03/24/2010CN100594883C Agent for treating alopecia and the preparing method thereof
03/24/2010CN100594863C Adhesive containing wound closure device and method
03/24/2010CN100594795C Fat and oil composition
03/23/2010WO2010107605A1 Cgrp receptor antagonists
03/23/2010US7683211 Jasmonate derivative compounds pharmaceutical compounds and methods of use thereof
03/23/2010US7683193 Inflammation, autoimmune disease and abnormal cell proliferation; analogs of 15-epi-lipoxin A4; e.g. (5S,6R,E)-methyl 5,6-dihydroxy-8-(2-(1-hydroxyhexyl)phenyl)oct-7-enoate
03/23/2010US7683181 Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof
03/23/2010US7683171 N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors
03/23/2010US7683166 RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
03/23/2010US7683165 RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
03/23/2010US7683164 Nucleic acid derivatives
03/23/2010US7683163 Colchicoside analogues
03/23/2010US7683160 1-chloro-4-( beta -D-glucopyranos-1-yl)-2-[4-((1R,2R)-2-hydroxy-cyclopent-1-yloxy)-benzyl]-benzene; metabolic disorders such as diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia; sodium-dependent glucose cotransporter SGLT2 inhibitors
03/23/2010US7683097 Topoisomerase inhibitors
03/23/2010US7683096 Acid amide derivatives, process for producing these, and pest control agent containing these
03/23/2010US7683095 Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
03/23/2010US7683094 2-(2-((2R)-2-heptylaminomethyl-5-oxopyrrolidin-1-yl)ethylthio)-1,3-thiazole-4-carboxylic acid; EP2 and/or EP4 receptor agonist; immune disease; antiallergens; alopecia; dysmenorrhea; erectile dysfuncction; antiarthritic agents; liver, respiratory, vascular, urogenital disorder
03/23/2010US7683093 N-1-[(4-chlorophenyl)]-N-2-{[4-(2{dimethylaminomethyl }phenyl)phenyl]-}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide; inhibitors of coagulation factor Xa; thromboembolic diseases; tumors
03/23/2010US7683092 type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome; indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists
03/23/2010US7683091 Substituted indoles and methods of their use
03/23/2010US7683090 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt
03/23/2010US7683089 4-[1-(2,3-dichloro-phenyl)-ethyl]-1,3-dihydro-imidazole-2-thione; cardiovascular and/or sedatory activity, pain; minimal side effects
03/23/2010US7683088 Compounds for the treatment of inflammatory disorders
03/23/2010US7683087 HIV infections; potent antiviral effects, particularly against mutated Reverse Transcriptases including K103N, Y181C and Y188L; 4-[2-(5-bromo-4-[7-methoxy-4-methylnaphthalen-1-yl]-4H-1,2,4-triazol-3-ylthio)acetamido]-3-chlorobenzoic acid
03/23/2010US7683086 Fungicidal mixtures
03/23/2010US7683085 novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction
03/23/2010US7683084 Thiazoline and oxazoline derivatives and their methods of use
03/23/2010US7683083 as sodium and calcium channels antagonist; 4'-Nitro-biphenyl-4-sulfonic acid thiazol-2-ylamide; antiinflammatory, analgesic, anxiolytic agent, antidepressant, neurodegenerative disorders; arthritis, migraine, trigeminal and herpetic neuralgia, epilepsy, arrhythmia, movement disorders
03/23/2010US7683082 1,2,4-oxadiazole benzoic acid compositions and their use in bioassays
03/23/2010US7683081 arthritis, allergic contact dermatitis, psoriasis, asthma, rheumatoid arthritis, or stroke; using producing coronary vasodilation without significant peripheral vasodilation
03/23/2010US7683080 purification from sulfide/sulfone derivatives; crystallization; proton pump inhibitors
03/23/2010US7683079 (cis)-3-phenyl-1-phenethyl-piperidine-4-yl-amine, (trans)-3-phenyl-1-phenethyl-piperidine-4-yl-amine; dipeptidyl-peptidase iv inhibitors; diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or beta -cell protection
03/23/2010US7683078 Neuronal disorders, autoimmune diseases, cancer, cardiovascular diseases; such as 4-Chloro-N-{5-[1-(4-trifluoromethyl-benzyl)-piperidin-3-ylsulfamoyl]-25 thiophen-2-ylmethyl)-benzamide
03/23/2010US7683077 Piperidine derivative
03/23/2010US7683076 N-(4-chlorophenyl)-N-(3-hydroxy-1-methyl-1,2,3,4-tetrahydroquinolin-5-yl)urea; vanilloid receptor (VR1) antagonistic; urinary incontinence, pain, rheumatoid arthritis, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders, asthma and chronic obstructive pulmonary disorder
03/23/2010US7683074 Antiinflammatory agents; antiallergens; neurodegrative disease ; autoimmune disease; antiarthritic agents
03/23/2010US7683073 Isoquinoline-1,3,4-trione compounds, the synthetic method and the use thereof
03/23/2010US7683072 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
03/23/2010US7683071 for treatment of focal distonia, tremors, and parkinson's disease; administering sodium salt of 5,5-diphenyl barbituric acid
03/23/2010US7683070 insecticides for soil-borne insects, such as termites and white grubs; less costly and safer to use on crops; N-{4-[(4-{bis[4-(trifluoromethyl)phenyl]methylene}piperidyl)methyl]phenyl}ethoxycarboxamide, N-oxide
03/23/2010US7683069 3-substituted-4-pyrimidone derivatives
03/23/2010US7683068 Emesis, urinary incontinence, depression, and anxiety; substance P inhibitors; 5-{1-[3,5-bis(Trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindole
03/23/2010US7683067 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3)
03/23/2010US7683066 Isoquinolines useful as modulators of ion channels
03/23/2010US7683065 Pyridines useful as modulators of ion channels
03/23/2010US7683064 Inhibitors of Bruton's tyrosine kinase
03/23/2010US7683063 inhibiting Vanilloid Receptor 1; Inflammatory bowel disease; Crohn's disease and ulcerative colitis; cyclo(hetero)alkenyl compound
03/23/2010US7683062 of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide; dysfunction of peripheral-type benzodiazepine receptors; anticarcinogenic, antiinflammatory agent, neurodegenerative diseases; stresses, arthritis; improved bioavailability, solubility, storage stability
03/23/2010US7683061 rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis; reduced drug toxicity
03/23/2010US7683060 3-[1-(4-Methoxyphenyl)cyclopropyl]-6-phenyl[1,2,4]triazolo[4,3-b][1,2,4]triazine; cancer and other diseases related to the dysregulation of kinase pathways; c-Met inhibitors
03/23/2010US7683059 Triazole compounds and uses related thereto
03/23/2010US7683057 Kinase inhibitor compounds
03/23/2010US7683056 Pyridine derivatives and their use in the treatment of psychotic disorders
03/23/2010US7683055 Lanthionine-related compounds for the treatment of inflammatory diseases
03/23/2010US7683054 solid oral dosage form comprising about 75 to 600 mg of aliskiren or a hemi-fumarate salt thereof; maximum plasma concentration of drug from 26 to 420 ng/mL between 1 and 3 hours after administering; renin inhibitor; antihypertensives for treating congestive heart failure; industrial scale manufacture
03/23/2010US7683053 Phenyl-piperazine derivatives as serotonin reuptake inhibitors
1 ... 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 ... 7860